These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Ukrainian break-through in the European and world strategy of individual prophylaxis of ischemic stroke in patients with arterial hypertension]. Tolstopiatov SM Lik Sprava; 2010; (5-6):3-21. PubMed ID: 21488364 [TBL] [Abstract][Full Text] [Related]
29. Thrombosis in cardiovascular medicine: a review of pathophysiology, mechanisms of drug action, and the "alphabet" of established and emerging therapies. McCarthy J; Szeto J Methodist Debakey Cardiovasc J; 2011; 7(4):2-5. PubMed ID: 22143468 [TBL] [Abstract][Full Text] [Related]
30. Coagulation Defects in the Cirrhotic Patient Undergoing Liver Transplantation. Parker A; Karvellas CJ Transplantation; 2018 Sep; 102(9):1453-1458. PubMed ID: 29757897 [TBL] [Abstract][Full Text] [Related]
31. Coagulation abnormalities in the cirrhotic patient. Muciño-Bermejo J; Carrillo-Esper R; Uribe M; Méndez-Sánchez N Ann Hepatol; 2013; 12(5):713-24. PubMed ID: 24018489 [TBL] [Abstract][Full Text] [Related]
32. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Arshad F; Lisman T; Porte RJ Liver Int; 2013 Jul; 33(6):820-7. PubMed ID: 23490221 [TBL] [Abstract][Full Text] [Related]
33. Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment. Hartmann M; Szalai C; Saner FH World J Gastroenterol; 2016 Jan; 22(4):1541-50. PubMed ID: 26819521 [TBL] [Abstract][Full Text] [Related]
34. ESH-ESC guidelines for the management of hypertension. Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473 [TBL] [Abstract][Full Text] [Related]
35. Recent Advances in the Understanding of Thrombosis. Satoh K; Satoh T; Yaoita N; Shimokawa H Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):e159-e165. PubMed ID: 31116608 [No Abstract] [Full Text] [Related]
36. Thrombosis and the hypercoagulable state. Ratnoff OD Circulation; 1984 Nov; 70(5 Pt 2):III72-76. PubMed ID: 6488506 [TBL] [Abstract][Full Text] [Related]
37. Evidence against hypercoagulability in coronary artery disease. Görög P; Ridler CD; Rees GM; Kovacs IB Thromb Res; 1995 Aug; 79(4):377-85. PubMed ID: 7482441 [TBL] [Abstract][Full Text] [Related]
38. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. Remková A; Kratochvíl'ová H; Durina J J Hum Hypertens; 2008 May; 22(5):338-45. PubMed ID: 18305548 [TBL] [Abstract][Full Text] [Related]
39. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. Lip GY; Blann AD J Hypertens; 1998 Oct; 16(10):1557-9. PubMed ID: 9814630 [No Abstract] [Full Text] [Related]
40. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Nadar SK; Tayebjee MH; Messerli F; Lip GY Curr Pharm Des; 2006; 12(13):1581-92. PubMed ID: 16729871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]